Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors
Journal Title: Turkish Journal of Hematology - Year 2019, Vol 36, Issue 1
Abstract
Over the last 50 years, the survival rates in children with acute lymphoblastic leukemia (ALL) have increased remarkably. The optimal use of antileukemic agents in cooperative group protocols, central nervous system-directed treatment, improvements in supportive care, and recognition of biological, clinical, and treatment response characteristics that predict patients with a higher or a lower risk of treatment failure have improved 5-year event-free survival rates, reaching more than 85%, and 5-year overall survival rates, reaching more than 90%. Consequently, it has become increasingly important to characterize the occurrence of long-term late effects. ALL treatments have been associated with increased risks for adverse outcomes such as late mortality, secondary malignancies, and neurological, cardiac, endocrine, and social/psychological disorders. In recent decades, cooperative groups in Europe and in the United States have provided essential information about the long-term effects of ALL therapy, giving recommendations for screening as well as facilitating new approaches for reducing late-term morbidity and mortality. Current frontline protocols continue to examine ways to lower the intensity and amount of therapy to reduce late effects, whereas survivorship studies attempt to predict such adverse effects precisely and develop targeted prevention and treatment strategies.
Authors and Affiliations
Hande Kızılocak, Fatih Okcu
Keywords
Related Articles
- EP ID EP543430
- DOI 10.4274/tjh.galenos.2018.2018.0150
- Views 70
- Downloads 0
Aortic aneurysm and non-Hodgkin’s lymphoma in Marfan syndrome
The combination of Marfan syndrome with lymphoma is extremely rare. This report describes a case of Marfan syndrome who presented with chest discomfort and was diagnosed to have an aortic aneurysm and an additional incid...
Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases
Objective: Ankaferd hemostat (Ankaferd Blood Stopper®, ABS)- induced pharmacological modulation of essential erythroid proteins can cause vital erythroid aggregation via acting on fibrinogen gamma. Topical endoscopic ABS...
Kawasaki Hastalığında Hematolojik Bulgular ile Koroner Arter Anevrizması Arasındaki İlişki
Chediak-Higashi Syndrome in Accelerated Phase Masquerading as Acute Leukemia
.
Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia
To the Editor, The most frequent side effects of bortezomib are fatigue, hematologic toxicity with cytopenias, and peripheral neuropathy, whereas postural hypotension and hyponatremia are less common late side effects [...